Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus Infections | 24 | 2024 | 176 | 5.810 |
Why?
|
| Influenza, Human | 32 | 2023 | 360 | 3.840 |
Why?
|
| Respiratory Syncytial Virus, Human | 21 | 2024 | 137 | 3.600 |
Why?
|
| Respiratory Tract Infections | 22 | 2024 | 251 | 3.590 |
Why?
|
| Hospitalization | 22 | 2024 | 392 | 2.020 |
Why?
|
| Infant | 50 | 2024 | 2145 | 1.740 |
Why?
|
| Child, Preschool | 47 | 2024 | 1675 | 1.660 |
Why?
|
| South Africa | 73 | 2024 | 7312 | 1.460 |
Why?
|
| HIV Infections | 28 | 2023 | 4946 | 1.460 |
Why?
|
| Child | 37 | 2024 | 2180 | 1.280 |
Why?
|
| Humans | 86 | 2024 | 14077 | 1.280 |
Why?
|
| Virus Diseases | 4 | 2023 | 55 | 1.200 |
Why?
|
| Coinfection | 13 | 2019 | 268 | 1.160 |
Why?
|
| Population Surveillance | 9 | 2019 | 325 | 0.920 |
Why?
|
| Cost of Illness | 7 | 2022 | 155 | 0.830 |
Why?
|
| Communicable Diseases | 1 | 2023 | 61 | 0.810 |
Why?
|
| Prospective Studies | 25 | 2024 | 1131 | 0.780 |
Why?
|
| Male | 39 | 2024 | 6489 | 0.730 |
Why?
|
| Seasons | 14 | 2024 | 149 | 0.730 |
Why?
|
| Sentinel Surveillance | 7 | 2024 | 110 | 0.730 |
Why?
|
| Female | 46 | 2024 | 8751 | 0.710 |
Why?
|
| Adolescent | 31 | 2024 | 2858 | 0.680 |
Why?
|
| Aged | 23 | 2024 | 1650 | 0.680 |
Why?
|
| Prevalence | 15 | 2023 | 1149 | 0.670 |
Why?
|
| Middle Aged | 30 | 2024 | 3425 | 0.650 |
Why?
|
| Infant, Newborn | 18 | 2024 | 1410 | 0.620 |
Why?
|
| Viruses | 6 | 2022 | 47 | 0.610 |
Why?
|
| Young Adult | 25 | 2024 | 2357 | 0.600 |
Why?
|
| Adult | 35 | 2024 | 5664 | 0.590 |
Why?
|
| Influenza Vaccines | 5 | 2021 | 132 | 0.550 |
Why?
|
| Vaccination | 10 | 2023 | 347 | 0.520 |
Why?
|
| Diarrhea | 5 | 2017 | 76 | 0.510 |
Why?
|
| Incidence | 11 | 2024 | 655 | 0.500 |
Why?
|
| Global Health | 5 | 2023 | 183 | 0.460 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 449 | 0.460 |
Why?
|
| Pneumococcal Infections | 3 | 2023 | 287 | 0.420 |
Why?
|
| Orthomyxoviridae | 6 | 2020 | 33 | 0.410 |
Why?
|
| Rhinovirus | 3 | 2019 | 23 | 0.400 |
Why?
|
| Epidemics | 2 | 2024 | 64 | 0.390 |
Why?
|
| Respiratory Syncytial Viruses | 3 | 2023 | 28 | 0.390 |
Why?
|
| Rotavirus Infections | 3 | 2017 | 46 | 0.360 |
Why?
|
| Rotavirus Vaccines | 3 | 2017 | 53 | 0.360 |
Why?
|
| Acute Disease | 5 | 2017 | 105 | 0.350 |
Why?
|
| Cost-Benefit Analysis | 6 | 2023 | 235 | 0.340 |
Why?
|
| Epidemiological Monitoring | 4 | 2019 | 45 | 0.320 |
Why?
|
| Cohort Studies | 8 | 2024 | 939 | 0.290 |
Why?
|
| Picornaviridae Infections | 2 | 2019 | 18 | 0.280 |
Why?
|
| Streptococcus pneumoniae | 6 | 2023 | 320 | 0.280 |
Why?
|
| Caliciviridae Infections | 2 | 2017 | 11 | 0.270 |
Why?
|
| Rural Population | 5 | 2021 | 624 | 0.270 |
Why?
|
| Nasopharynx | 8 | 2023 | 148 | 0.270 |
Why?
|
| Pneumonia, Pneumococcal | 3 | 2015 | 93 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2015 | 507 | 0.220 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.220 |
Why?
|
| Hospital Mortality | 5 | 2023 | 94 | 0.210 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 41 | 0.210 |
Why?
|
| Risk Factors | 8 | 2024 | 1431 | 0.210 |
Why?
|
| Whooping Cough | 1 | 2023 | 36 | 0.210 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 90 | 0.200 |
Why?
|
| Tuberculosis | 2 | 2019 | 530 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2021 | 53 | 0.190 |
Why?
|
| Pregnancy | 8 | 2023 | 1815 | 0.190 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 29 | 0.190 |
Why?
|
| Housing | 1 | 2021 | 24 | 0.180 |
Why?
|
| Pandemics | 5 | 2023 | 280 | 0.180 |
Why?
|
| Air Pollution, Indoor | 1 | 2021 | 13 | 0.180 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.180 |
Why?
|
| Rural Health | 1 | 2021 | 118 | 0.180 |
Why?
|
| Genotype | 3 | 2017 | 430 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 260 | 0.180 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 243 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 104 | 0.170 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 5 | 0.170 |
Why?
|
| Absenteeism | 1 | 2019 | 10 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2019 | 31 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 42 | 0.160 |
Why?
|
| Metapneumovirus | 2 | 2016 | 29 | 0.160 |
Why?
|
| Pneumococcal Vaccines | 2 | 2023 | 252 | 0.150 |
Why?
|
| Community Health Services | 1 | 2018 | 58 | 0.150 |
Why?
|
| Rotavirus | 1 | 2017 | 29 | 0.140 |
Why?
|
| Norovirus | 1 | 2017 | 5 | 0.140 |
Why?
|
| Immunization Programs | 2 | 2017 | 78 | 0.140 |
Why?
|
| Bacteremia | 2 | 2014 | 79 | 0.140 |
Why?
|
| Public Health Surveillance | 4 | 2019 | 52 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 77 | 0.130 |
Why?
|
| Sapovirus | 1 | 2016 | 6 | 0.130 |
Why?
|
| Respirovirus | 1 | 2015 | 4 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2016 | 28 | 0.130 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2015 | 10 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 3 | 2021 | 542 | 0.130 |
Why?
|
| Influenza B virus | 1 | 2016 | 42 | 0.130 |
Why?
|
| Disease Outbreaks | 2 | 2013 | 111 | 0.130 |
Why?
|
| Adenoviridae | 1 | 2015 | 39 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 128 | 0.130 |
Why?
|
| Pneumovirus Infections | 1 | 2015 | 7 | 0.130 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 11 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 23 | 0.120 |
Why?
|
| Developing Countries | 2 | 2017 | 385 | 0.120 |
Why?
|
| Bronchopneumonia | 1 | 2015 | 11 | 0.120 |
Why?
|
| Vaccines, Conjugate | 1 | 2015 | 161 | 0.120 |
Why?
|
| HIV-1 | 3 | 2012 | 1239 | 0.110 |
Why?
|
| Viral Fusion Proteins | 1 | 2013 | 11 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2013 | 31 | 0.110 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 60 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1377 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2021 | 149 | 0.110 |
Why?
|
| History, 21st Century | 3 | 2019 | 37 | 0.110 |
Why?
|
| Models, Theoretical | 3 | 2019 | 78 | 0.110 |
Why?
|
| Patient Compliance | 3 | 2009 | 120 | 0.110 |
Why?
|
| Urban Population | 3 | 2021 | 246 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 102 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2014 | 169 | 0.110 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 22 | 0.100 |
Why?
|
| Measles | 1 | 2013 | 36 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2012 | 54 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2019 | 464 | 0.100 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 266 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 56 | 0.100 |
Why?
|
| Age Distribution | 3 | 2024 | 106 | 0.100 |
Why?
|
| Carrier State | 2 | 2023 | 89 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 320 | 0.100 |
Why?
|
| Phylogeny | 3 | 2017 | 231 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2021 | 132 | 0.090 |
Why?
|
| Propylene Glycols | 1 | 2009 | 3 | 0.090 |
Why?
|
| Phosphates | 1 | 2009 | 10 | 0.090 |
Why?
|
| Glycerol | 1 | 2009 | 8 | 0.090 |
Why?
|
| Cellulose | 1 | 2009 | 21 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.090 |
Why?
|
| Fever | 2 | 2019 | 25 | 0.080 |
Why?
|
| Herpesvirus 2, Human | 1 | 2009 | 42 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2019 | 767 | 0.080 |
Why?
|
| Contraceptive Devices, Female | 1 | 2009 | 29 | 0.080 |
Why?
|
| Herpes Genitalis | 1 | 2009 | 42 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2009 | 29 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2020 | 168 | 0.080 |
Why?
|
| World Health Organization | 2 | 2020 | 134 | 0.080 |
Why?
|
| Age Factors | 2 | 2024 | 364 | 0.080 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 11 | 0.080 |
Why?
|
| Kenya | 2 | 2023 | 173 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 380 | 0.080 |
Why?
|
| United States | 2 | 2021 | 129 | 0.070 |
Why?
|
| Community Health Centers | 1 | 2007 | 9 | 0.070 |
Why?
|
| Occupations | 1 | 2007 | 13 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 56 | 0.070 |
Why?
|
| Australia | 2 | 2018 | 46 | 0.070 |
Why?
|
| Feces | 2 | 2017 | 30 | 0.070 |
Why?
|
| Comorbidity | 2 | 2019 | 184 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2007 | 101 | 0.070 |
Why?
|
| Algorithms | 2 | 2021 | 105 | 0.070 |
Why?
|
| Mass Screening | 2 | 2019 | 242 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 235 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2009 | 467 | 0.060 |
Why?
|
| Time Factors | 2 | 2019 | 503 | 0.060 |
Why?
|
| Singapore | 1 | 2024 | 3 | 0.060 |
Why?
|
| New Zealand | 1 | 2024 | 8 | 0.060 |
Why?
|
| Viral Interference | 1 | 2024 | 2 | 0.060 |
Why?
|
| Molecular Epidemiology | 2 | 2014 | 44 | 0.060 |
Why?
|
| Linear Models | 1 | 2024 | 82 | 0.060 |
Why?
|
| Bacterial Load | 2 | 2014 | 32 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 171 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 263 | 0.060 |
Why?
|
| Bordetella pertussis | 1 | 2023 | 29 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 150 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 409 | 0.050 |
Why?
|
| Markov Chains | 1 | 2021 | 20 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 106 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 137 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 405 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 100 | 0.050 |
Why?
|
| Computational Biology | 1 | 2021 | 43 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cooking | 1 | 2021 | 7 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 247 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 210 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 1275 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.040 |
Why?
|
| Cough | 1 | 2019 | 13 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 25 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 15 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2019 | 21 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 41 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 30 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 36 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 86 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 73 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 197 | 0.040 |
Why?
|
| Vietnam | 1 | 2018 | 11 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 46 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 46 | 0.030 |
Why?
|
| Animals | 1 | 2019 | 1063 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2017 | 303 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 21 | 0.030 |
Why?
|
| Cross Protection | 1 | 2016 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 64 | 0.030 |
Why?
|
| Paramyxoviridae Infections | 1 | 2016 | 26 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 63 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 18 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2015 | 22 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 131 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Suburban Population | 1 | 2014 | 9 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 102 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 101 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 2 | 0.030 |
Why?
|
| Egypt | 1 | 2013 | 4 | 0.030 |
Why?
|
| Guatemala | 1 | 2013 | 8 | 0.030 |
Why?
|
| Weather | 1 | 2013 | 7 | 0.030 |
Why?
|
| Bangladesh | 1 | 2013 | 14 | 0.030 |
Why?
|
| Thailand | 1 | 2013 | 24 | 0.030 |
Why?
|
| Climate | 1 | 2013 | 5 | 0.030 |
Why?
|
| China | 1 | 2013 | 21 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 54 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 263 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 180 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 24 | 0.030 |
Why?
|
| Pharynx | 1 | 2012 | 4 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2012 | 9 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2012 | 7 | 0.030 |
Why?
|
| Oropharynx | 1 | 2012 | 17 | 0.030 |
Why?
|
| Measles Vaccine | 1 | 2013 | 34 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 38 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 268 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2009 | 21 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 38 | 0.020 |
Why?
|
| Vulva | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2009 | 21 | 0.020 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2009 | 24 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2009 | 50 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 22 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 38 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 95 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 124 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 44 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 56 | 0.020 |
Why?
|
| Vagina | 1 | 2009 | 91 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 88 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 263 | 0.020 |
Why?
|
| Recreation | 1 | 2007 | 4 | 0.020 |
Why?
|
| Food Industry | 1 | 2007 | 11 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 532 | 0.020 |
Why?
|
| Program Development | 1 | 2007 | 32 | 0.020 |
Why?
|
| Tanzania | 1 | 2007 | 84 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2009 | 867 | 0.020 |
Why?
|